Passage Bio Inc. (PASG): Price and Financial Metrics

Passage Bio Inc. (PASG): $1.24

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add PASG to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#60 of 362

in industry

PASG Price/Volume Stats

Current price $1.24 52-week high $1.79
Prev. close $1.24 52-week low $0.58
Day low $1.24 Volume 121
Day high $1.24 Avg. volume 372,752
50-day MA $1.35 Dividend yield N/A
200-day MA $0.93 Market Cap 76.40M

PASG Stock Price Chart Interactive Chart >


Passage Bio Inc. (PASG) Company Bio


Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.


PASG Latest News Stream


Event/Time News Detail
Loading, please wait...

PASG Latest Social Stream


Loading social stream, please wait...

View Full PASG Social Stream

Latest PASG News From Around the Web

Below are the latest news stories about PASSAGE BIO INC that investors may wish to consider to help them evaluate PASG as an investment opportunity.

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted an inducement award to a new employee. Passage Bio granted options to purchase 10,400 shares of common stock to this employee as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise pric

Yahoo | November 17, 2023

Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

On track to present initial safety and biomarker data from three Cohort 1 patients in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations (GRN) in Q4 2023Expect to report initial safety and biomarker data from Dose 3 patients in global Phase 1/2 Imagine-1 clinical trial for gangliosidosis (GM1) in mid-2024Robust balance sheet to support achievement of meaningful clinical milestones, with cash runway into Q4 2025 PHILA

Yahoo | November 13, 2023

Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference

PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference on Monday, November 6, 2023 at 2:30 p.m. ET. A live webcast of the event will be available on

Yahoo | October 30, 2023

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted inducement awards to new employees. Passage Bio granted options to purchase 50,000 shares of common stock to these employees as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price

Yahoo | October 20, 2023

Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference

PHILADELPHIA, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines Conference on Monday, October 2, 2023 at 5:00 p.m ET. A live webcast of the event will be available on the Investors & Media

Yahoo | September 25, 2023

Read More 'PASG' Stories Here

PASG Price Returns

1-mo -15.07%
3-mo 32.65%
6-mo 88.45%
1-year 15.89%
3-year -92.19%
5-year N/A
YTD 22.77%
2023 -26.81%
2022 -78.27%
2021 -75.17%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!